You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020654658341
Dec 2020300300158
Jan 2021360360156
Feb 2021206206117
Mar 2021152152105
Apr 202114214292
May 202117617680
Jun 202112912983
Jul 2021131131100
Aug 202117117185
Sep 202115215272
Oct 2021178178116
Nov 2021293293106
Dec 202114114388
Jan 202216717876
Feb 202223425082
Mar 2022201209108
Apr 202218318697
May 202217918199
Jun 202218619799
Jul 202218819099
Aug 202214615087
Sep 202214815181
Oct 202226026382
Nov 202216116579
Dec 202213413761
Jan 202312312360
Feb 202314815179
Mar 202316316769
Apr 202311211495
May 202311812167
Jun 202312512578
Jul 202313313366
Aug 202316917378
Sep 202314714982
Oct 202319819980
Nov 202333533588
Dec 202316516788
Jan 2024118120104
Feb 202417017280
Mar 2024151151126
Apr 2024184186120
May 2024138143112
Jun 2024979980
Jul 202414414670
Aug 202414314675
Sep 202412312375
Oct 202413613678
Nov 202420020263
Dec 202413113468
Jan 202514915089
Feb 202527927987
Mar 202518018079
Apr 202518919094
May 2025154154127
Jun 202510410953
Total10098102255259